Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 14;16(11):1883–1890. doi: 10.1038/mt.2008.181

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Newcastle disease virus (NDV) combination therapy in immunocompetent BALB/c mice. Ten mice per group were subcutaneously implanted with 5 × 10⁵ CT26.CL25 cells. When tumors reached a size of 5–8 mm in diameter, mice were intratumorally treated with phosphate-buffered saline (PBS), 1 × 10⁷ plaque forming units of NDV/F3aa-GFP, NDV/F3aa-minigal, NDV/F3aa-minigal + NDV/F3aa-GFP, NDV/F3aa-GFP + NDV/F3aa-IL-2, or NDV/F3aa-minigal + NDV/F3aa-IL-2 every 2 days for a total of four injections. (a) Tumor volumes were monitored every 2 days during experimental period. (b) Percentage of complete regressions per treatment group is indicated. Surviving mice were challenged with CT26.CL25 60 days post-treatment initiation and percentage protection is also shown. GFP, green fluorescent protein.